Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

计划入组 10 人 · 首次发布于 2025 年 7 月 3 日

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

计划入组 200 人 · 首次发布于 2024 年 3 月 15 日

South Asian Arrhythmogenic Cardiomyopathy Registry

计划入组 100 人 · 首次发布于 2021 年 5 月 20 日

LMNA gene therapy (LMNA-related dilated cardiomyopathy)

cardiomyopathy program

Cardiomyopathy(Kate Therapeutics)

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Lexeo Therapeutics Launches $100M IPO to Advance Gene Therapy Pipeline

Rocket Pharmaceuticals to Present First Phase 1 Data for Gene Therapy in Rare Heart Condition at ASGCT

Lexeo Therapeutics Secures $80M Financing to Advance Genetic Heart Disease Therapies